机器人立体定向体部放疗治疗局限性前列腺癌的10年疗效与生化及临床结局的相关性
本研究纳入82例接受五分割机器人立体定向体部放疗(SBRT,35-37.5 Gy)的局限性前列腺癌患者,中位随访11.0年。10年生化失败无生存率为86.3%,临床失败无生存率为86.7%,癌症特异生存率100%;每日治疗与更优生化控制相关,PSA最低点出现时间较长与更优临床控制相关。
要点
- 10年生化失败无生存率86.3%,临床失败无生存率86.7%,癌症特异生存率100%。
- 每日SBRT较隔日治疗的生化失败无生存更优(HR 0.220,95%CI 0.067-0.720,p=0.012)。
- PSA最低点出现间隔≥5年与更优临床失败无生存相关(HR 0.120,95%CI 0.015-0.944,p=0.044)。
核心结论
- 机器人SBRT治疗局限性前列腺癌显示出持久的长期疗效,每日治疗安排与PSA最低点出现间隔是关键预后指标。
研究设计与样本
- 回顾性分析82例接受五分割SBRT(35-37.5 Gy)的局限性前列腺癌患者,中位随访11.0年(范围3.3-15.9年)。
主要发现
- 10年生化失败无生存率为86.3%(95%CI 78.6-94.8),临床失败无生存率为86.7%(95%CI 78.8-95.4)。
- 观察到9例生化失败,局部转移1例、区域转移2例、远处转移5例,癌症特异生存率100%。
- PSA最低点中位值0.09 ng/ml(范围0.0-3.12),达到PSA最低点的中位间隔52.8个月(范围0.4-170.2)。
- PSA最低点出现时间与PSA最低点值呈负相关(r=-0.233,p=0.035)。
关键数值与推荐
- 每日SBRT对比隔日治疗:生化失败无生存HR 0.220(95%CI 0.067-0.720,p=0.012)。
- PSA最低点出现间隔≥5年:临床失败无生存HR 0.120(95%CI 0.015-0.944,p=0.044)。
临床怎么用
- 对局限性前列腺癌行机器人SBRT时,可优先考虑每日治疗安排以改善生化控制。
- 治疗后应重视PSA动力学监测,PSA最低点出现较晚者临床控制可能更好。
局限性
- 样本量较小(82例),为单中心长期随访数据,结论需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Long-term data on the efficacy of robotic stereotactic body radiotherapy (SBRT) for localized prostate cancer (LPC) remain limited. This study aimed to evaluate the 10-year treatment outcomes of SBRT in LPC patients and identify key prognostic factors. METHODS: A total of 82 patients with LPC who underwent five-fraction SBRT (doses of 35-37.5 Gy) were included. The median follow-up duration was 11.0 years (range, 3.3-15.9 years). Clinical outcomes, including the biochemical failure-free survival (BCFFS), clinical failure-free survival (CFFS), and prostate-specific antigen (PSA) kinetics, were analyzed to evaluate the impact of various clinical and treatment factors on prognosis. RESULTS: The 10-year BCFFS and CFFS rates were 86.3% (95% confidence interval [CI], 78.6-94.8) and 86.7% (95% CI, 78.8-95.4), respectively. Nine cases of biochemical failure were observed, alongside local (n = 1), regional (n = 2), and distant (n = 5) metastases. The cancer-specific survival rate was 100%. The median PSA nadir was 0.09 ng/ml (range, 0.0-3.12 ng/ml) and the median interval to PSA nadir was 52.8 months (range, 0.4-170.2 months). There was a negative correlation between the time to the PSA nadir and the PSA nadir value (r = -0.233, p = 0.035). Daily SBRT was associated with improved BCFFS compared to every-other-day treatment (hazard ratio [HR], 0.220; 95% CI, 0.067-0.720; p = 0.012), while a longer interval to PSA nadir (≥ 5 years) was associated with better CFFS (HR, 0.120; 95% CI, 0.015-0.944; p = 0.044). CONCLUSIONS: Robotic SBRT for LPC demonstrates durable long-term efficacy. Daily treatment schedules and interval to PSA nadir were identified as crucial prognostic indicators. These findings highlight the importance of PSA kinetics in predicting treatment success following robotic SBRT.
引用
- Kim JS, Park Y, Park HJ, et al. Correlations of biochemical and clinical outcomes with 10-year results after robotic stereotactic body radiotherapy for localized prostate cancer. Radiat Oncol. 2025. PMID: 41131547. doi:10.1186/s13014-025-02739-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。